272 related articles for article (PubMed ID: 10414735)
1. Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy.
Ghavamian R; Blute ML; Bergstralh EJ; Slezak J; Zincke H
Urology; 1999 Jul; 54(1):105-10. PubMed ID: 10414735
[TBL] [Abstract][Full Text] [Related]
2. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice.
Amling CL; Blute ML; Lerner SE; Bergstralh EJ; Bostwick DG; Zincke H
Mayo Clin Proc; 1998 May; 73(5):401-6. PubMed ID: 9581578
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy.
Cookson MS; Fleshner NE; Soloway SM; Fair WR
Urology; 1997 Jun; 49(6):887-93. PubMed ID: 9187696
[TBL] [Abstract][Full Text] [Related]
4. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features.
Krumholtz JS; Carvalhal GF; Ramos CG; Smith DS; Thorson P; Yan Y; Humphrey PA; Roehl KA; Catalona WJ
Urology; 2002 Sep; 60(3):469-73; discussion 473-4. PubMed ID: 12350486
[TBL] [Abstract][Full Text] [Related]
6. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
7. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
[TBL] [Abstract][Full Text] [Related]
8. Is it necessary to separate clinical stage T1c from T2 prostate adenocarcinoma?
Armatys SA; Koch MO; Bihrle R; Gardner TA; Cheng L
BJU Int; 2005 Oct; 96(6):777-80. PubMed ID: 16153198
[TBL] [Abstract][Full Text] [Related]
9. Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease.
Antenor JA; Roehl KA; Eggener SE; Kundu SD; Han M; Catalona WJ
Urology; 2005 Jul; 66(1):156-60. PubMed ID: 15992903
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control.
Pound CR; Partin AW; Epstein JI; Walsh PC
Urol Clin North Am; 1997 May; 24(2):395-406. PubMed ID: 9126237
[TBL] [Abstract][Full Text] [Related]
11. Assessment of relative tumor burden in patients with clinical T1c prostate cancer treated with either external beam or radical prostatectomy.
Hintz BL; Murphy JS; Kaswick JA; Bellman GC; Ruel CJ; Kagan AR
Am J Clin Oncol; 1999 Aug; 22(4):332-7. PubMed ID: 10440185
[TBL] [Abstract][Full Text] [Related]
12. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer.
Amling CL; Lerner SE; Martin SK; Slezak JM; Blute ML; Zincke H
J Urol; 1999 Mar; 161(3):857-62; discussion 862-3. PubMed ID: 10022701
[TBL] [Abstract][Full Text] [Related]
13. Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer.
Hoedemaeker RF; Rietbergen JB; Kranse R; van der Kwast TH; Schröder FH
World J Urol; 1997; 15(6):339-45. PubMed ID: 9436283
[TBL] [Abstract][Full Text] [Related]
14. Implications of greater short-term PSA recurrence with laparoscopic as compared to retropubic radical prostatectomy for Japanese clinically localized prostate carcinomas.
Akita H; Okamura T; Ando R; Nagata D; Naruyama H; Yamada Y; Naiki T; Yasui T; Tozawa K; Kohri K
Asian Pac J Cancer Prev; 2011; 12(11):2959-61. PubMed ID: 22393971
[TBL] [Abstract][Full Text] [Related]
15. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
[TBL] [Abstract][Full Text] [Related]
16. Pathological characteristics and prognosis of nonpalpable and palpable prostate cancers with a Hybritech prostate specific antigen of 4 to 10 ng./ml.
Geary ES; Stamey TA
J Urol; 1996 Sep; 156(3):1056-8. PubMed ID: 8709306
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis.
Lerner SE; Seay TM; Blute ML; Bergstralh EJ; Barrett D; Zincke H
J Urol; 1996 Mar; 155(3):821-6. PubMed ID: 8583584
[TBL] [Abstract][Full Text] [Related]
18. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis.
Partin AW; Criley SR; Subong EN; Zincke H; Walsh PC; Oesterling JE
J Urol; 1996 Apr; 155(4):1336-9. PubMed ID: 8632568
[TBL] [Abstract][Full Text] [Related]
19. Comparison of T1c versus T2 prostate cancers in Japanese patients undergoing radical prostatectomy.
Furuya Y; Ohta S; Sato N; Kotake T; Masai M
Int Urol Nephrol; 2002; 33(1):73-6. PubMed ID: 12090344
[TBL] [Abstract][Full Text] [Related]
20. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
